Comparing Minerva Neurosciences (NASDAQ:NERV) and Relmada Therapeutics (NASDAQ:RLMD)

Relmada Therapeutics (NASDAQ:RLMD) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Relmada Therapeutics and Minerva Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-170.83%	-145.58%
Minerva Neurosciences	N/A	-41.35%	-35.62%

Risk and Volatility

Relmada Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500.

Earnings & Valuation

This table compares Relmada Therapeutics and Minerva Neurosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.45)	-4.80
Minerva Neurosciences	N/A	N/A	-$293.42 million	($26.80)	-0.23

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by insiders. Comparatively, 10.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Relmada Therapeutics and Minerva Neurosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1	1	4	1	2.71
Minerva Neurosciences	1	1	0	0	1.50

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 72.41%. Minerva Neurosciences has a consensus price target of $7.00, indicating a potential upside of 16.09%. Given Relmada Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Relmada Therapeutics is more favorable than Minerva Neurosciences.

Summary

Relmada Therapeutics beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.